Metabolic · GLP-1 receptor agonist
What is happening with META-24 right now?
Synthetic demo data
Active patients
700
Strong responders
252 / 36%
At-risk patients
105
Intervention opportunities
40
match trajectories that benefited from GI-04
Predicted discontinuations / 30 d
76
Emerging clusters
3
Predicted vs observed
Baseline model expectation against what the trajectories actually did.
| Metric | Predicted | Observed |
|---|---|---|
| Response | 60% | 71% |
| Severe GI toxicity | 12% | 8% |
| Discontinuation | 14% | 11% |
| Treatment persistence | 82% | 88% |
LIFE OS learned this week
All insightsA new treatment-response phenotype emerged
90 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 36; clinical recognition has typically come at day 92.
40 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 21% and 74% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 4.7× more likely to reach high discontinuation risk than the program average (116 patients).
Unexpected strong responders
25 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.